Share ownership ImmunityBio, Inc.

IBRX

US45256X1037

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 20:00:00 10/03/2026 GMT			5-day change	1st Jan Change
8.010 ^USD	-5.21%		-19.90%	+304.55%

03-09	ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data	CI
03-09	ImmunityBio Resubmits Supplemental Biologics License Application for Cancer Treatment Anktiva	MT

Share class: ImmunityBio, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	730,328,430	159,907,150 ( 21.9 %)	163,800 ( 0.0224 %)	21.9 %

Major shareholders: ImmunityBio, Inc.

Name	Equities	%	Valuation
Patrick Soon-Shiong 39.42 %	388,299,926	39.42 %	2 427 M $
Cambridge Equities LP 26.57 %	261,705,814	26.57 %	1 636 M $
Vanguard Fiduciary Trust Co. 3.328 %	32,777,257	3.328 %	205 M $
BlackRock Advisors LLC 2.371 %	23,351,194	2.371 %	146 M $
STATE STREET CORPORATION 1.671 %	16,455,703	1.671 %	103 M $
Jane Street Group LLC 1.444 %	14,224,224	1.444 %	89 M $
Geode Capital Management LLC 0.8041 %	7,920,178	0.8041 %	50 M $
Goldman Sachs Asset Management LP 0.6247 %	6,152,684	0.6247 %	38 M $
Morgan Stanley Capital Services LLC 0.5184 %	5,106,214	0.5184 %	32 M $
Two Sigma Investments LP 0.479 %	4,717,843	0.479 %	29 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Individuals	39.86%
Other	29.4%
Institutional	12.45%
State Street Corp.	1.67%
Skandinaviska Enskilda Banken AB	0.13%
Schweizerische Nationalbank	0.07%
Manulife Financial Corp.	0.02%
Rathbones Group Plc	0.02%
Regions Financial Corp.	0.01%
SEI Investments Co.	0.01%
Unknown	16.36%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	42.34%
Individuals	39.87%
United Kingdom	0.91%
Ireland	0.15%
Sweden	0.15%
Switzerland	0.08%
Canada	0.05%
Germany	0.02%
China	0.02%
Austria	0.02%
Japan	0.01%
Norway	0.01%

Based on 1000 largest holdings

Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as infectious diseases. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising, B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA and recombinant protein vaccines, and cell therapies. Its lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein.

Employees

688

Sector

Biotechnology & Medical Research

More about the company